Immunotherapy Breakthroughs in the Treatment of Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

SIMPLE SUMMARY: Head and neck squamous cell carcinoma (HNSCC), in the locally advanced setting, relapses in more than 50% of cases after surgery and/or chemo-radiotherapy. Prognosis is then very poor with platinum-based chemotherapy yielding a median survival of 10 months and a 2-year survival rate...

Descripción completa

Detalles Bibliográficos
Autores principales: Borel, Christian, Jung, Alain C., Burgy, Mickaël
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563963/
https://www.ncbi.nlm.nih.gov/pubmed/32967162
http://dx.doi.org/10.3390/cancers12092691

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7563963/
https://www.ncbi.nlm.nih.gov/pubmed/32967162
http://dx.doi.org/10.3390/cancers12092691

Ejemplares similares